Purpose: The purpose of this work was to accurately characterize the spectral properties of hyperpolarized 129 Xe in patients with idiopathic pulmonary fibrosis (IPF) compared to healthy volunteers. Methods: Subjects underwent hyperpolarized 129 Xe breathhold spectroscopy, during which 38 dissolved-phase free induction decays (FIDs) were acquired after reaching steady state (echo time/repetition time ¼ 0.875/50 ms; bandwidth ¼ 8.06 kHz; flip angle%22
INTRODUCTION
Hyperpolarized (HP) 129 Xe MRI has emerged as a viable alternative to 3 He for functional pulmonary MRI. This transition has created growing interest in exploiting the solubility of 129 Xe and its $200 parts per million (ppm) in vivo chemical shifts to comprehensively assess lung function. This enormous range of chemical shifts is caused by the large and polarizable electron cloud of xenon, through which the 129 Xe atom experiences changes in the degree of nuclear shielding as it transiently binds to various macromolecules within the body (1) . Conveniently, the 129 Xe binding affinities and degree of chemical exchange are governed by tissue properties; therefore, the anatomical and physiological state of the lung determines the 129 Xe spectral characteristics. The chemical shifts of 129 Xe have been investigated by spectroscopic techniques both in vitro and in vivo. Early in vitro studies of 129 Xe dissolved in human blood revealed two distinct dissolved-phase resonances (2) . By separating red blood cells (RBCs) from plasma, 129 Xe resonances from these two compartments were found to be separated by roughly 22 ppm. Subsequent in vitro work refined the assignment of plasma to 198 ppm and RBCs to 217 ppm (3) (4) (5) (6) . Interestingly, Wolber et al found that the line width of the plasma peak increases linearly with hematocrit, and also demonstrated that the chemical shift of the RBC peak is strongly and nonlinearly affected by oxygenation level (6, 7) . These oxygenation effects were recently confirmed by Norquay et al, who measured a 5.5-ppm range of 129 Xe-RBC chemical shifts when in vitro blood s0 2 values ranged from 0.1 to 1 (8) .
Subsequent in vivo studies found that 129 Xe in the lung had similar spectral characteristics to those reported in vitro. Despite significant spectral broadening imparted by the inhomogeneous susceptibility environment in the lung, two dissolved-phase 129 Xe resonances could be readily observed. The RBC peak has been generally reported at 217 ppm in humans, whereas the 198-ppm peak has been assigned to 129 Xe dissolved in both plasma and other pulmonary tissues. This latter resonance is therefore commonly referred to as the "tissue/plasma" or "barrier" peak. By monitoring how these dissolved-phase peaks vary in vivo, 129 Xe has begun to show promise as a biomarker for multiple diseases and physiological processes. These have included measures of blood oxygenation (7, 8) , brain perfusion (9, 10) , and weight regulation through brown adipose tissue stimulation (11) . However, the most widely investigated application has been the characterization of pulmonary gas transfer (12) (13) (14) (15) . These studies exploit the fact that individual 129 Xe resonances directly reflect the dynamics of 129 Xe diffusing between the airspaces, interstitial barrier tissues, and capillary blood. For example, Kaushik et al investigated 129 Xe spectra from subjects with idiopathic pulmonary fibrosis (IPF) and reported that the ratio of the RBC to barrier signal was reduced by more than 3-fold relative to that in healthy subjects (16) . Moreover, this work demonstrated that the ratio of 129 Xe uptake in RBC versus barrier correlated strongly with the diffusing capacity for carbon monoxide (DL CO ), the most common clinical marker of gas transfer. Kaushik et al also found that subjects with IPF exhibited a negative frequency shift in the RBC peak, which was interpreted as reflecting diminished blood oxygenation in the capillary beds.
Such spectroscopic findings not only provide sensitive measurements of lung function at a global scale, but they are also key to enabling phase-sensitive imaging techniques that spatially resolve gas transfer. Recently, several such techniques, originally developed for fat-water separation, were extended to separate the 129 Xe signal in RBCs from that in barrier tissues (17, 18) . Such methods generally require acquiring dissolved-phase images at sufficient signal to noise ratio (SNR) and then using prior spectral knowledge to decompose images of the constituent resonances. The challenges of acquiring high-quality dissolved-phase images in vivo have been overcome by pairing an undersampled 3D radial acquisition with an optimized reconstruction (19, 20) . However, the second step of decomposing the dissolved-phase image remains an active area of research. Proper decomposition requires accurate information about the spectral characteristics of each resonance. However, such spectral characterization remains challenging because the resonances are broad and overlapping in the lung.
To date, the methods to decompose the dissolved-phase 129 Xe spectral properties have been somewhat rudimentary relative to 1 H and 13 C spectroscopy, where sophisticated modeling techniques have been developed that incorporate knowledge of the coupling between protons and carbon atoms in various compounds (21, 22) . However, these advanced tools have not been readily applied to 129 Xe spectra. That is because 129 Xe is an inert gas with no J-coupling, but it does exhibit significant exchange and susceptibility broadening. Therefore, its spectrum can be accurately modeled by just two phenomena-precession and exponential decay. The challenge with 129 Xe spectroscopy lies in accurately accounting for the broad and overlapping nature of these resonances, as well as the substantial phase variation between them.
This work seeks to introduce techniques to better analyze 129 Xe spectra acquired in human lungs. Using nonlinear curve fitting to decompose complex 129 Xe free induction decays (FIDs) in the time domain, we demonstrate that the spectrum of 129 Xe in human lungs is accurately characterized by not two, but three dissolved-phase resonances. We report the frequencies, linewidths, and phases of these three resonances in a cohort of healthy normal and IPF subjects. We then illustrate the key differences in spectral characteristics between the two populations. This work suggests that incorporating the knowledge that three dissolvedphase 129 Xe resonances arise within the lung could offer not only additional functional information in its own right, but could also improve the quality of phase-sensitive gas-transfer imaging.
METHODS

Subject Recruitment
This study was approved by the Duke Institutional Review Board. Before participating, all subjects provided written informed consent. The population consisted of 12 healthy normal (8 males and 4 females; 32.1 6 13.8 years old) and 12 volunteers with IPF (10 males and 2 females; 68.5 6 7.2 years old) who underwent HP 129 Xe spectroscopy as part of a broader imaging protocol. Before spectroscopy, all subjects completed pulmonary function testing, which included measuring the total lung capacity (TLC), functional residual capacity (FRC), forced vital capacity (FVC), and DL CO .
Xenon Polarization and Delivery
Using a commercially available polarizer (Model 9810; Polarean, Inc., Durham, NC), 300 mL of isotopically enriched 129 Xe (85%) were hyperpolarized to $20% by spin-exchange optical pumping. HP 129 Xe was cryogenically accumulated, thawed into a 1-L Tedlar bag, and diluted with 700 mL of ultra-high-purity N 2 to achieve a net 1-L volume with a 51-mL dose equivalent of HP 129 Xe (23) . Immediately preceding delivery to the subject, the polarization of each dose was measured and recorded by a polarimeter (Model 2881; Polarean, Inc.).
Xe Spectroscopy
Both gas-and dissolved-phase spectra were acquired on a 1.5 Tesla GE Healthcare 15M4 EXCITE MRI scanner using a quadrature 129 Xe vest coil (Clinical MR Solutions, Brookfield, WI). For each subject, heart rate and oxygen saturation were monitored using an MRcompatible monitoring system (Expression Model 865214; Invivo Corporation, Orlando, FL). Each subject was instructed to twice inhale to TLC, then exhale to FRC before inhaling the 1-L gas mixture for the 13-second breath hold. The spectroscopic parameters for the gas-and dissolved-phase 129 Xe FIDs were: 512 samples per FID, echo time/repetition time ¼ 0.875/50 ms; bandwidth ¼ 8.06 kHz; 1.2-ms three-lobe sinc pulse; and flip angle%0. 5/22 . Because these spectra also served as a calibration for subsequent imaging, we maintained the same 22 dissolved-phase flip angle used during imaging so that this parameter remained consistent between both sequences. In lieu of using a 90 flip angle to eliminate magnetization that had accumulated downstream of the Three Dissolved-Phase capillary beds, we instead discarded the first 48 dissolved-phase FIDs. We then averaged the 38 remaining steady-state frames in order to maximize FID SNR before curve fitting.
Spectroscopic Processing
The complex FIDs from the single gas-phase and averaged dissolved-phase excitations were individually decomposed using a custom MATLAB toolkit (The MathWorks, Inc., Natick, MA). This open-source code is available for research use from www.civm.duhs.duke.edu/NmrSpectroscopy. The toolkit models each FID as a summation of precessing and exponentially decaying components (24) . Each component signal is described by four parameters: an amplitude (a n ); starting phase (f n ); resonant frequency (f n ); and line width (w n ). Using these parameters, the fitted signal, s fit , can be calculated at any time, t, according to Equation [1] :
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Using a trust-region-reflective algorithm, this code iteratively solves for the parameters that minimize the least squares error between the measured and fitted data in the time domain (25) . Unlike more common frequencydomain fitting methods, this approach does not require using line broadening, zero padding, or parameter constraints. However, to preserve convention, spectra are shown in the frequency domain. Also, we report timedomain amplitudes of each peak, but note that due to properties of the Fourier transform, this is equivalent to the spectral peak area in the frequency-domain. Fit results were compared after allowing for either two or three dissolved-phase resonances. Because the RBC resonance was most straightforward to isolate, its starting phase was set to zero and those of the barrier resonances were reported relative to it. In order to establish an absolute frequency reference against which to report the chemical shift of each component, we decomposed the dedicated gas-phase spectrum into two resonances, representing 129 Xe in the airways and alveoli (26) . The stability of these resonances was evaluated in a subpopulation of 7 subjects by comparing their relative gasphase frequencies to those of both thermally polarized 129 Xe in a phantom and hyperpolarized 129 Xe in a dose bag. We found that in humans, unlike in mice (26), the airway peak exhibits the most stable frequency. The frequency of this airway peak was adjusted by the known shift from Xe-Xe collisions (0.03 ppm for 0.3 atmospheres of Xe partial pressure) to establish our 0 ppm reference. With this reference, the alveolar peak appeared, on average, at À2.3 ppm. This is reasonably close to the À2.9 ppm predicted from bulk magnetic susceptibility shifts (À3.02 ppm) for a spherical alveolus (26) corrected for Xe-O 2 (0.09 ppm) and Xe-Xe (0.03 ppm) collisions.
Statistical Analysis
All statistical analysis was performed in MATLAB (The MathWorks, Inc.). Differences between healthy normal and IPF cohorts were evaluated using a Mann-WhitneyWilcoxon U test, and determined to be statistically significant if P < 0.05. The coefficient of determination (r 2 ) was used to assess correlations between spectroscopically derived metrics and pulmonary function test (PFT) results.
RESULTS
Decomposing the Dissolved-Phase 129 Xe Spectrum
When fitting the 129 Xe spectrum from both subject groups, significant and patterned residual error persisted until three dissolved-phase resonances were included in the fit. This is illustrated in Figure 1a , showing a representative dissolved-phase 129 Xe FID (top) and spectrum (bottom) from a subject with IPF. Although the net-fitted signal from two peaks (blue line) appears to match the measured spectrum (large black circles at discrete spectral sampling points) reasonably well, the residual error (small red circles) shows distinct spectral oscillation in the region of dissolved-phase signal. When a third peak was introduced into the fit (Fig. 1b) , these fluctuations were eliminated and the residual error dropped to the noise floor. Using the three-peak fit, the RBC resonance maintained similar amplitude and phase, but its line width became broader and its frequency shifted positively by $3.5 ppm relative to the two-peak fit results. This was related to a second observation that fitting to three peaks caused the barrier peak to split into two resonances that were $5 ppm apart. These two peaks individually had smaller amplitudes than the single barrier peak derived from the two-peak fit; they were both broader, and their starting phases were strikingly different considering their proximal frequencies. Throughout this work, we refer to the higher-frequency peak as barrier 1 and to the lower-frequency as barrier 2.
Allowing for three dissolved-phase peaks also improved the fit quality in healthy subjects, although less dramatically than for subjects with IPF. This is illustrated in Figure 2 , depicting a representative dissolved-phase 129 Xe FID (top) and spectrum (bottom) decomposed into two versus three peaks. Fitting only two peaks resulted in residual error with a similar oscillating pattern, although of smaller magnitude than for the IPF subject. This was again eliminated by decomposing the FID into three resonances. As with the IPF subject, the three-peak fitting also found the chemical shift of the RBC peak to be more positive than the two-peak fitting. In the healthy subject, the line width and phase of the RBC peak were similar between the two-and three-peak fits. The two-peak barrier resonance again split into two resonances that were individually less intense, broader, and $4.7 ppm apart.
Quantifying Spectral Parameters From Twoand Three-Peak Fits Figure 3 compares RBC:barrier ratios derived from twoand three-peak fits; in the latter case, termed RBC:barriers for clarity, this ratio is calculated by dividing the RBC amplitude by the sum of both barrier peak amplitudes. In the two-peak fit, RBC:barrier was reduced by 65.1% in IPF versus healthy subjects (P < 0.001), whereas in the three-peak fit the reduction was only 47.1% (P < 0.001). This difference is driven by the inclusion of the third dissolved-phase peak, which yielded lower RBC:barrier(s) in healthy subjects, but did not substantially affect this ratio in subjects with IPF. Figure 4 illustrates how the chemical shifts, line widths, and starting phases varied when the FID was decomposed into two versus three peaks in our healthy normal and IPF cohorts. Using a two-peak fit (Fig. 4a) found the RBC peak to be 3.15 ppm more negative (P < 0.001) and the barrier peak to be 0.45 ppm more negative in IPF versus healthy subjects (P ¼ 0.03). Similarly, two-peak fitting reported line widths that were 2.15 ppm narrower for the RBC peak (P < 0.001) and 1.04 ppm narrower for the barrier peak (P < 0.001) in subjects with IPF versus healthy subjects. Using only a two-peak fit caused the starting phase of the RBC peak to be highly variable in subjects with IPF. Moreover, this starting 129 Xe spectrum in a representative healthy subject. (a) Using two peaks resulted in residual error that was small, but patterned in the time and spectral domains. (b) The error was reduced to the noise floor by decomposing the spectrum into three peaks.
FIG. 2. Decomposing the dissolved-phase
FIG. 3.
For both two-and three-peak fits, the RBC:barrier ratio is statistically reduced in IPF subjects relative to healthy subjects. *Statistical difference between groups (P < 0.05).
Three Dissolved-Phase phase was 54.9 higher (P < 0.001) in subjects with IPF relative to healthy subjects.
Using a three-peak fit instead, the RBC resonance in subjects with IPF was only 0.70 ppm more negative than in healthy volunteers (P ¼ 0.05). The chemical shift of barrier 1 was not statistically different between the two cohorts (P ¼ 0.21), but barrier 2 was 0.6 ppm more negative (P ¼ 0.009). Using the three-peak fit, the line width of the RBC peak was indistinguishable between groups (P ¼ 0.80). However, three-peak fitting reported line widths for barriers 1 and 2 that were 3.2 (P < 0.001) and 2.0 ppm narrower (P < 0.001) in IPF versus healthy subjects. In patients with IPF, the phase of the barrier 1 peak was 20.2 higher compared to healthy normal subjects (P ¼ 0.01). The phase of barrier 2 was consistent between subjects with IPF versus healthy subjects (P ¼ 0.19).
Spectroscopic Measurements Illustrate Differences Between IPF and Healthy Subjects
Because decomposing the FIDs into three peaks eliminated residual error and patterns in both groups, only the three-peak fit parameters and spectral SNR are summarized in Table 1 . Spectral SNR was defined as the magnitude of the fitted signal divided by the magnitude of the residual error. Pulmonary function test results are also included for each subject. Figure 5 shows that the three-peak RBC:barriers ratio strongly correlated with both DL CO and FVC. The correlation was stronger with DL CO (r 2 ¼ 0.84; P < 0.001) than with FVC (r 2 ¼ 0.71, P < 0.001). Both correlation plots separated the cohorts of IPF and healthy subjects, although they were further separated in the DL CO correlation.
DISCUSSION
Modeling the Dissolved-Phase 129 Xe Spectrum
To date, the in vivo 129 Xe spectrum in human lungs has been reported to consist of only two dissolved-phase resonances. This is likely attributed, in part, because previous studies involved primarily healthy subjects, where the two barrier resonances are much broader. Thus, the presence of three dissolved-phase peaks is less evident than it is in IPF subjects, where both barrier resonances become narrower and barrier 2 shifts slightly away from barrier 1. An additional reason this third peak has likely eluded detection is because robust curve-fitting methods have not generally been applied to 129 Xe spectroscopy. The most prevalent method for decomposing the dissolved-phase 129 Xe spectrum has been to phase correct the spectrum to first order and visually identify peaks. For each resonance, its signal amplitude is estimated by integrating the peak area, its frequency is determined by the location of the local peak maxima, and its line width is approximated from the measured peak full width at half Three Dissolved-Phase maximum (FWHM). This approach, though readily available, has several limitations. First, because the dissolved 129 Xe resonances are broad and close in frequency, it is difficult to accurately identify resonant frequencies visually. The high degree of overlap and differences in starting phase can obscure peaks entirely, or the tails of a nearby resonance can shift local maxima away from their true positions. Second, when peaks overlap significantly, calculating line widths from FWHMs becomes impossible. Third, this overlap reduces the accuracy of area under the curve measurements. Fourth, applying only zero-and first-order phase corrections does not allow the multiple dissolved-phase peaks to be simultaneously in phase with the receiver, making measurements of peak integrals, frequencies, and line widths impossible to quantify accurately.
Although recent years have seen increasingly moresophisticated approaches to fitting 129 Xe spectra (8, 16, 27) , the model used in this work has three key advantages: 1) fitting is performed in the time domain; 2) it accounts for differences in starting phase among individual peaks; and 3) it simultaneously considers both the real and imaginary signals to minimize the complex error. By fitting in the time domain, we minimize the error between the fitted model and the actual acquired data. Furthermore, time-domain fitting avoids artifacts that can be introduced by additional processing steps such as zero padding and line broadening (16) . Zero padding in the time domain, particularly with long-lived signals that have not fully decayed by the end of the FID, can introduce spectral ringing as an artifact of truncating the FID. Therefore, spectral-domain fitting seeks to reduce such truncation artifacts by line broadening the signal, which apodizes the long-lived FID using an exponential decay function preceding Fourier transformation. By contrast, fitting in the time domain eliminates the need for Fourier transformation, rendering it immune to these truncation artifacts. In addition, the fitting method used here allows each peak to retain an individual starting phase. This is particularly important given that acquiring dissolved-phase 129 Xe spectra without contamination from the much more abundant gas-phase signal requires using long, frequency-selective pulses. This delays the start of FID acquisition, during which each peak accumulates significant additional phase. Therefore, it is essential that the fitting routine incorporate different starting phases for each resonance by fitting the absorptive and dispersive components in the real and imaginary channels simultaneously.
Fitting the 129 
Xe Spectrum Requires Three Dissolved-Phase Resonances
Including a third dissolved-phase peak into the spectral decomposition more accurately fit the measured signal for both subject groups. Although the magnitude of the net residual error could have been decreased further by introducing additional spectral components, we found them to have areas on the order of the noise floor, whereas their other spectral characteristics varied widely across subjects. Thus, error reduction achieved by decomposing more than three dissolved-phase peaks is attributable to overfitting. In contrast, three dissolvedphase peaks were consistently necessary to eliminate the structure noted in the residual error, and all three peaks had reproducible frequencies and line widths. This suggests that our findings are not merely a consequence of overfitting, and rather that the dissolved-phase 129 Xe spectrum consists of three resonances. We can further conclude that this evidence of a third dissolved-phase peak is not a consequence of averaging FIDs because we were able to decompose single FIDs into three dissolvedphase peaks with reasonable agreement between subsequent FIDs. However, we suggest averaging at least five FIDs to obtain sufficient SNR to reproducibly characterize all of the dissolved-phase peaks.
Decomposing the FIDs into three dissolved-phase resonances also made the spectral parameters of the RBC peak more consistent across subjects. As seen in Figure  4 , without the third resonance, the RBC frequency and starting phase were highly variable among IPF subjects. Including the third peak caused both the RBC frequency and its starting phase to become stable across subjects. Moreover, it eliminated differences in RBC line width between IPF patients and healthy subjects. This suggests that when using only two-peak fits, the RBC peak must absorb part of the signal from the missing barrier peak, causing its spectral parameters to become sensitive to changes in barrier signal. By introducing the third dissolved-phase resonance, the RBC peak becomes untangled from barrier 1, and its spectral parameters become stable across subjects. Whereas including a third peak improves the fit of the RBC peak, it also must split the single-barrier peak into two. Given that they are broad and close in frequency, this makes them difficult to fit in healthy subjects. As a result, the spectral parameters of the barrier peaks varied slightly more in healthy subjects using the three-peak fit than the two-peak fit.
RBC:Barriers Is Reduced in IPF
In aggregate, three-peak fitting has identified six spectral parameters that exhibited statistically significant changes between IPF and healthy subjects. This speaks to the rich information contained in the dissolved-phase 129 Xe spectrum. The most significant of these changes was that RBC:barriers was 47.1% lower in IPF versus healthy subjects (P < 0.001). This reduction was less than the 65.1% difference obtained using only a two-peak fit. This difference is caused predominantly by three-peak fits producing larger barrier amplitudes in healthy subjects. Because barriers 1 and 2 are nearly perfectly out of phase, this causes the two-peak fit to underestimate the overall barrier signal and consequently overestimate RBC:barrier. Nonetheless, RBC:barriers strongly correlated with DL CO (r 2 ¼ 0.84; P < 0.001), which is similar to the correlation of 0.89 we previously reported using two-peak fits (16) . Such strong correlations with the primary marker of gas transfer suggests that this reduction in RBC:barriers reflects on a combination of interstitial thickening, which restricts the diffusion of 129 Xe into the RBCs, and diminished capillary blood volume, caused by regional perfusion deficits.
RBC Frequency Is Decreased in IPF, Whereas RBC Line Width Remains Unchanged
Further insights into the gas-exchange dynamics can be gained by examining both the RBC line width and frequency. By using three-peak fits, the RBC peak line width remained consistent between IPF and healthy subjects at $11.5 ppm. This stands in contrast to the apparent narrowing that had previously been reported in IPF when using the two-peak fit (16) . This suggests that RBCs experience essentially the same physical environment in the capillary beds of healthy and IPF subjects. However, the in vivo RBC line width we measure here is still broader than the 8.6-ppm line width reported for 129 Xe in RBCs in vitro (6) . This broadening likely arises from the inhomogeneous lung environment.
Similarly, the three-peak fits reduced the magnitude of the apparent RBC frequency shift in patients with IPF. We did observe a 0.7-ppm negative shift for the RBC peak in IPF, but this was much smaller than reported in our initial studies, which used two-peak fits to report a shift of À2.4 ppm in these patients (16) . In fact, applying the same two-peak fits to the present study, we measured a similar, albeit more pronounced À3.15-ppm negative shift of the RBC peak in IPF subjects. Thus, it now appears that this larger apparent RBC shift in the twopeak fits was primarily a consequence of incompletely decomposing the spectrum. We now understand, from our three-peak fit, that the barrier consists of two resonances, which, in IPF, are both more intense and narrower. Therefore, when the dissolved-phase spectrum was fit to only two peaks, a portion of the missing barrier peak was allocated to the RBC resonance. This caused the least squares fitting solution to miscalculate both the frequency, line width, and phase of the RBC resonance.
The RBC frequency shift is of particular importance in light of in vitro work demonstrating that this resonance can shift by as much as 5.5 ppm, depending on blood oxygenation (5) . Thus, the relatively modest negative shift of 0.7 ppm for the RBC resonance we now report suggests that capillary blood in IPF patients is not as poorly oxygenated as previously thought. Although we must acknowledge that there may still be local regions where blood is poorly oxygenated, our whole-lung spectroscopic measure of blood oxygenation indicates that, even in IPF, the RBCs are, on average, still well oxygenated. Nonetheless, temporal changes in oxygenation should be observable in 129 Xe spectra acquired during prolonged breath hold. This was demonstrated in healthy volunteers by Norquay et al, where a decrease of up to 1 ppm in RBC frequency was detected over the course of a 35-second breath hold (8) .
Possible Origins of the Two Barrier Peaks
Although the physical origin of the two barrier peaks remains to be confirmed, this work provides important clues to their sources. The acquisition methods used here were designed to minimize downstream magnetization, such that the measured signal, and its constituent resonances, must spatially originate near the lung's gasexchange regions. We can also deduce how the barrier peaks interact physiologically by noting that, unlike the RBCs, the line widths of the barrier resonances became significantly narrower in IPF. This narrowing could be caused by diminished chemical exchange between these compartments or decreased susceptibility driven distortions of the local magnetic field. Diminished chemical exchange could be the result of the two-barrier compartments becoming physically larger and more spatially separated in IPF. Alternatively, spectral narrowing could be caused by the reduced surface area and geometric changes of the air-tissue interfaces given that barrier tissues occupy an increasingly larger fraction of the lungs in IPF subjects. This possibility is bolstered by changes in the starting phases of barriers 1 and 2 during the submillisecond delay between excitation and readout. First, the two-barrier resonances were $100 out of phase with one another. This phase dispersion cannot be explained by chemical shifts alone because the two peaks are separated by only 83 Hz (4.7 ppm). Instead, we hypothesize that the phase differences between these two components arise during the long duration of RF excitation in the presence of the inhomogeneous magnetic field environment of the lung. Second, the starting phase of barrier 1 was 20.2 higher in IPF subjects versus healthy subjects (P ¼ 0.01). This leads us to suspect that barrier 1 may originate from areas closest to the lung's air-tissue interfaces, where susceptibility differences are greatest. This premise is further reinforced by the line width of barrier 1 being broader than that of barrier 2. Therefore, we hypothesize that the barrier 1 peak represents tissue residing close to the alveolar wall and its associated large susceptibility gradient caused by neighboring airspaces. Barrier 2 is substantially narrower, with a line width in IPF patients that is nearly identical to the 7.2-ppm in vitro line width measured in plasma (6) . Moreover, it also has a chemical shift near that of 129 Xe in water (196 ppm) (1) . For these reasons, we postulate that barrier 2 arises from both plasma and aqueous inflammatory processes residing in the interstitial space.
Study Limitations
In this work, we administered a fixed gas volume for all subjects, regardless of individual lung volumes. Ideally, each subject would have inhaled a gas volume equal to a known proportion of their TLC, in order to control for lung inflation effects. However, breath coaching subjects to an exact lung inflation level is challenging without resorting to moreinvasive means, such as mechanical ventilation. Moreover, recent work by Qing et al found that the effects of lung inflation are most severe at residual volume, most strongly affect the dissolved:gas ratios, and do not affect measures of alveolar septal thickness (28) . Because our interest here is in the dissolved-phase compartments, and given that our spectra were acquired at $60% of TLC for healthy volunteers and $80% for subjects with IPF, we expect differences in inflation to affect our results only modestly.
Given the difficulty of normalizing dissolved-phase spectra to the gas-phase signal, we instead chose to normalize our spectral intensities to the sum of both barrier signals. Our findings clearly indicate that RBC:barriers is reduced in IPF; however, it is not able to reliably inform on whether RBC signal is diminished or the barrier signals are increased. If gas-phase signal could be acquired such that it originates only from the gas-exchange regions, this would serve as a better quantitative reference, given that it represents the source magnetization for RBC and barrier peaks (16, 28) . To this end, future studies should strive to spatially constrain the gas-phase signal either by selective excitation or perhaps by applying diffusion weighting to preserve 129 Xe signal from the alveoli, while suppressing signal from large airways. Alternatively, we can exploit the spatial information afforded by imaging to only calculate these ratios within the gas-exchange regions on a voxel-by-voxel basis.
And, finally, our healthy and IPF populations had significant differences in mean age; thus, our findings must be attributed to a combination of age and disease effects. It would be useful in the future to acquire additional data from a cohort of healthy volunteers that are age matched to IPF subjects. This would enable us to compare both the age effects between the two healthy cohorts, as well as the effects of disease between the IPF subjects and age-matched controls.
CONCLUSION
In this work, we illustrated the advantages of using complex time-domain fitting to decompose 129 Xe FIDs acquired in the human lung. By using these sensitive spectroscopic techniques, we uncovered evidence of a third dissolved-phase resonance, which aids in characterizing the spectral differences between healthy subjects and those with IPF. We confirm that the RBC:barriers ratio continues to be significantly reduced in subjects with IPF compared to healthy subjects. However, we reconsider the magnitude of our previously reported negative frequency shifts in RBC resonance among subjects with IPF. We now suggest that the magnitude of these shifts may have been overestimated as a result of decomposing a three-peak spectrum using only two peaks. This small change in global oxygenation, combined with no detectible change in the RBC line width, suggests that the diffusional limitation imposed by IPF at rest may not be as significant as previously thought.
The wealth of functional information in these FIDs leaves a vast space for future spectroscopic research, including temporal dynamics, longitudinal changes, regional variation, and applicability to other diseases. The existence of a third dissolved-phase peak also necessitates investigating the impact on the one-point Dixon methods for decomposing RBC and barrier images. It may suggest that, to the extent possible, and given the very short T2* of these components, separate imaging of these resonances may be improved by multiecho imaging techniques methods such as IDEAL (18) .
